1. Stocks
    2. /
  2. Pfizer Inc. (NYSE: PFE)
    3. /

Pfizer Inc. (NYSE: PFE) Share Price and News

$26.00 $0.61 (2.4%) Saturday, 20 April 2024 at 6:00:00 am Australian Eastern Standard Time

Pfizer Inc. Chart and Price Data

About Pfizer

Last updated 20-04-2024, 06:00:00am AEST
Current Price $26.00
Change $0.61 (2.4%)
Close Price $26.00
Open Price $25.39
Bid $25.85
Ask $25.93
Day Range $25.35 - $26.00
Year Range $25.23 - $40.37
Volume 38,372,801
Average Volume 42,827,804
Market Cap $146,816,280,000.00
Earnings Per Share $0.36

    • Pfizer Inc. (NYSE: PFE)
    Latest News

    A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
    International Stock News

    2 top trends to invest $2,000 in ahead of the crowd

    | Alex Carchidi

    These two trends on the frontier of medicine could present lucrative opportunities for investment.

    Read more »

    A child covering his eyes hiding from a toy bear representing a bear market for ASX shares
    International Stock News

    3 steps you'll regret not taking during this bear market

    | Alex Carchidi

    The last step is by far the hardest.

    Read more »

    a medical person in full protective clothing holds a tray of Covid-19 vaccinations amid a haze caused by cold and ice.
    Healthcare Shares

    ResApp share price frozen as $180m Pfizer takeover bid hangs in the balance

    | Brooke Cooper

    The value of Pfizer's takeover bid may soon come to light.

    Read more »

    Stethoscope with a piggy bank and hundred dollar notes.
    ETFs

    A defensive ASX ETF for a recessionary environment: experts

    | Bernd Struben

    In an ageing world newly aware of the potential threats posed by pandemics, healthcare shares have received plenty of attention…

    Read more »

    smiling health care workers in a medical setting
    Healthcare Shares

    Imugene (ASX:IMU) share price leaps 9% on Pfizer, Merck deal

    | Bernd Struben

    Cooperation between drug developers could speed up the delivery of effective treatments.

    Read more »

    four excited doctors with their hands in the air
    ETFs

    Expert reveals top pandemic ETF play – up 58% in 12 months

    | Bernd Struben

    COVID variants are likely to drive longer-term demand for mRNA vaccines.

    Read more »

    A businesman's hands surround a circular graphic with a United States flag and dollar signs, indicating buying and selling US shares
    Share Market News

    ASX investors were buying Alibaba, Pfizer shares last week

    | Sebastian Bowen

    Which US shares were ASX investors buying last week?

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    Why the IDT (ASX:IDT) share price is rocketing 25% on Wednesday

    | Marc Sidarous

    The company claims it can make 100 million doses of mRNA vaccine within 18 months.

    Read more »

    girl receiving pfizer vaccine
    International Stock News

    Why Pfizer shot 4% higher on Tuesday

    | Eric Volkman

    New York City introduces a sweeping vaccination mandate, as authorities struggle to keep the coronavirus at bay.

    Read more »

    Bottle of tablets spilling over onto piles of US dollars
    International Stock News

    Why the Pfizer share price shot higher on Wednesday

    | Eric Volkman

    The company's powerful growth isn't only due to its coronavirus vaccine.

    Read more »

    Female patient receives Pfizer covid vaccine administered by female doctor
    Coronavirus News

    TGA approves Pfizer vaccine for kids aged 12-15 years old

    | Marc Sidarous

    The Therapeutics Goods Administration decided to approve the vaccine for kids late last night.

    Read more »

    A stressed woman with her head in her hands sits at her desk reading about falling ASX 200 mining shares on her laptop
    International Stock News

    Does This Shocking CDC Statement Mean Trouble for Pfizer and Moderna?

    | Adria Cimino

    It has to do with the companies' next step in the coronavirus vaccine rollout.

    Read more »

    Profile

    since

    Note